ekaterina-prokosheva
Ekaterina Prokoshev/ Shutterstock.com
14 August 2020PharmaJakob Wested and John Liddicoat

The right recipe for the repurposing omelette

The repurposing of drugs that have been approved for treating other viruses has gained unprecedented media attention during the  COVID-19 pandemic. Lawyers persistently criticise second  medical use patent claims as pointless, yet pharmaceutical companies continue to obtain and litigate them. Second medical use patents are probably valuable only occasionally and if standing alone, they are an unstable foundation for a business model.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Pharma
9 July 2026   Separate lawsuits target Indian and Taiwanese pharma companies as Exelixis seeks to keep rival cabozantinib products off the US market until key patents expire.
Pharma
7 July 2026   Leading women from the pharmaceutical and biotechnology sectors are among the more than 100 professionals recognised in a newly released Influential Women in IP 2026 list, which celebrates leadership, expertise and innovation.
Pharma
1 July 2026   Otsuka v Sun Pharma could redefine which pharmaceutical patents qualify for patent term extensions, with major implications for innovator companies, generic manufacturers and the future of market exclusivity in the country.